340 related articles for article (PubMed ID: 17293248)
41. AS04-adjuvanted human papillomavirus-16/18 vaccination: recent advances in cervical cancer prevention.
Schwarz TF
Expert Rev Vaccines; 2008 Dec; 7(10):1465-73. PubMed ID: 19053203
[TBL] [Abstract][Full Text] [Related]
42. Human papillomavirus infection and the development of cervical cancer and related genital neoplasias.
Paavonen J
Int J Infect Dis; 2007 Nov; 11 Suppl 2():S3-9. PubMed ID: 18162244
[TBL] [Abstract][Full Text] [Related]
43. Cervical cancer prevention in the era of prophylactic vaccines: a preview for gynecologic oncologists.
; Collins Y; Einstein MH; Gostout BS; Herzog TJ; Massad LS; Rader JS; Wright J
Gynecol Oncol; 2006 Sep; 102(3):552-62. PubMed ID: 16979432
[TBL] [Abstract][Full Text] [Related]
44. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine.
Olsson SE; Villa LL; Costa RL; Petta CA; Andrade RP; Malm C; Iversen OE; Høye J; Steinwall M; Riis-Johannessen G; Andersson-Ellstrom A; Elfgren K; von Krogh G; Lehtinen M; Paavonen J; Tamms GM; Giacoletti K; Lupinacci L; Esser MT; Vuocolo SC; Saah AJ; Barr E
Vaccine; 2007 Jun; 25(26):4931-9. PubMed ID: 17499406
[TBL] [Abstract][Full Text] [Related]
45. [Prophylactic and therapeutic vaccination against human papillomavirus].
Brun JL; Riethmuller D
J Gynecol Obstet Biol Reprod (Paris); 2007 Nov; 36(7):631-41. PubMed ID: 17822860
[TBL] [Abstract][Full Text] [Related]
46. Short version of the German evidence-based Guidelines for prophylactic vaccination against HPV-associated neoplasia.
Pathirana D; Hillemanns P; Petry KU; Becker N; Brockmeyer NH; Erdmann R; Gissmann L; Grundhewer H; Ikenberg H; Kaufmann AM; Klusmann J; Kopp I; Pfister H; Rzany B; Schneede P; Schneider A; Smola S; Winter-Koch N; Wutzler P; Gross G
Vaccine; 2009 Jul; 27(34):4551-9. PubMed ID: 19524337
[TBL] [Abstract][Full Text] [Related]
47. The prophylactic role for the human papillomavirus quadrivalent vaccine in males.
Yancey AM; Pitlick JM; Forinash AB
Ann Pharmacother; 2010; 44(7-8):1314-8. PubMed ID: 20501891
[TBL] [Abstract][Full Text] [Related]
48. HPV vaccination - a paradigm shift in public health.
May J
Aust Fam Physician; 2007 Mar; 36(3):106-11. PubMed ID: 17339969
[TBL] [Abstract][Full Text] [Related]
49. Assessing human papillomavirus vaccine efficacy and safety.
Hendrix SL
J Am Osteopath Assoc; 2008 Apr; 108(4 Suppl 2):S8-S12. PubMed ID: 18463363
[TBL] [Abstract][Full Text] [Related]
50. A human papillomavirus vaccine.
Med Lett Drugs Ther; 2006 Aug 14-28; 48(1241-1242):65-6. PubMed ID: 16977280
[TBL] [Abstract][Full Text] [Related]
51. New paradigm for prevention of cervical cancer.
Kaufmann AM; Schneider A
Eur J Obstet Gynecol Reprod Biol; 2007 Jan; 130(1):25-9. PubMed ID: 16973254
[TBL] [Abstract][Full Text] [Related]
52. Spotlight on quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine(Gardasil®) in the prevention of premalignant genital lesions, genital cancer, and genital warts in women.
McCormack PL; Joura EA
BioDrugs; 2011 Oct; 25(5):339-43. PubMed ID: 21942919
[TBL] [Abstract][Full Text] [Related]
53. A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccine.
Ault KA; Giuliano AR; Edwards RP; Tamms G; Kim LL; Smith JF; Jansen KU; Allende M; Taddeo FJ; Skulsky D; Barr E
Vaccine; 2004 Aug; 22(23-24):3004-7. PubMed ID: 15297048
[TBL] [Abstract][Full Text] [Related]
54. Human papillomavirus vaccines: an update for gynecologists.
Ault KA
Clin Obstet Gynecol; 2008 Sep; 51(3):527-32. PubMed ID: 18677145
[TBL] [Abstract][Full Text] [Related]
55. Prevalence and incidence of HPV genital infection in women.
Velicer C; Zhu X; Vuocolo S; Liaw KL; Saah A
Sex Transm Dis; 2009 Nov; 36(11):696-703. PubMed ID: 19652630
[TBL] [Abstract][Full Text] [Related]
56. Human papillomavirus: the burden of infection.
Wiley D; Masongsong E
Obstet Gynecol Surv; 2006 Jun; 61(6 Suppl 1):S3-14. PubMed ID: 16729902
[TBL] [Abstract][Full Text] [Related]
57. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries.
Goldie SJ; O'Shea M; Campos NG; Diaz M; Sweet S; Kim SY
Vaccine; 2008 Jul; 26(32):4080-93. PubMed ID: 18550229
[TBL] [Abstract][Full Text] [Related]
58. Epidemiology and natural history of genital human papillomavirus infection.
Weaver BA
J Am Osteopath Assoc; 2006 Mar; 106(3 Suppl 1):S2-8. PubMed ID: 16729554
[TBL] [Abstract][Full Text] [Related]
59. Prospects and prejudices of human papillomavirus vaccines in India.
Das BC; Hussain S; Nasare V; Bharadwaj M
Vaccine; 2008 May; 26(22):2669-79. PubMed ID: 18455843
[TBL] [Abstract][Full Text] [Related]
60. Impact of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine in a sexually active population of North American women.
Barr E; Gause CK; Bautista OM; Railkar RA; Lupinacci LC; Insinga RP; Sings HL; Haupt RM
Am J Obstet Gynecol; 2008 Mar; 198(3):261.e1-11. PubMed ID: 18313445
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
